Teneligliptin improves glycemic control with the reduction of postprandial insulin requirement in Japanese diabetic patients.

Abstract

Teneligliptin is a novel peptidomimetic-chemotype prolylthiazolidine-based inhibitor of dipeptidyl peptidase-4 (DPP-4). The aim of this study was to evaluate the effects of teneligliptin on 24 h blood glucose control and gastrointestinal hormone responses to a meal tolerance test, and to investigate the glucose-lowering mechanisms of teneligliptin. Ten… (More)
DOI: 10.1507/endocrj.EJ14-0393

Topics

  • Presentations referencing similar topics